JP2021529828A5 - - Google Patents

Info

Publication number
JP2021529828A5
JP2021529828A5 JP2021521941A JP2021521941A JP2021529828A5 JP 2021529828 A5 JP2021529828 A5 JP 2021529828A5 JP 2021521941 A JP2021521941 A JP 2021521941A JP 2021521941 A JP2021521941 A JP 2021521941A JP 2021529828 A5 JP2021529828 A5 JP 2021529828A5
Authority
JP
Japan
Prior art keywords
composition
use according
antibody
subject
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040601 external-priority patent/WO2020010254A1/en
Publication of JP2021529828A publication Critical patent/JP2021529828A/ja
Publication of JP2021529828A5 publication Critical patent/JP2021529828A5/ja
Pending legal-status Critical Current

Links

JP2021521941A 2018-07-03 2019-07-03 炎症性腸疾患を治療するための組成物及び方法 Pending JP2021529828A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693798P 2018-07-03 2018-07-03
US62/693,798 2018-07-03
PCT/US2019/040601 WO2020010254A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2021529828A JP2021529828A (ja) 2021-11-04
JP2021529828A5 true JP2021529828A5 (enExample) 2022-07-11

Family

ID=69059935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521941A Pending JP2021529828A (ja) 2018-07-03 2019-07-03 炎症性腸疾患を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20210261651A1 (enExample)
EP (1) EP3817771A4 (enExample)
JP (1) JP2021529828A (enExample)
KR (1) KR20210029217A (enExample)
CN (1) CN112739376A (enExample)
AU (1) AU2019297455A1 (enExample)
BR (1) BR112021000025A2 (enExample)
CA (1) CA3104402A1 (enExample)
IL (1) IL279859A (enExample)
MX (1) MX2021000069A (enExample)
SG (1) SG11202012774TA (enExample)
WO (1) WO2020010254A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162387A1 (en) * 2019-12-20 2021-06-24 Graham J. BRITTON Compositions and methods for treating inflammatory bowel disease
TW202227394A (zh) * 2020-09-11 2022-07-16 美商工匠生物科技股份有限公司 細菌毒素之小分子抑制劑
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN114409777B (zh) * 2022-01-20 2023-09-01 温玉荣 结直肠癌相关脆弱拟杆菌毒素蛋白激活体的特异性纳米抗体Nb3.27及其应用
EP4669344A2 (en) * 2023-02-21 2025-12-31 Salvitus, Inc. Recombinant phages, probiotic vaccines and therapeutic agents, combined compositions and methods of use
CN116410324A (zh) * 2023-05-24 2023-07-11 西安交通大学医学院第一附属医院 一种肠道微生物脆弱拟杆菌毒素中和纳米抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
WO2010115092A2 (en) * 2009-04-02 2010-10-07 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
US20130045874A1 (en) * 2010-03-01 2013-02-21 Institut National De La Recherche Agronomique Method of Diagnostic of Inflammatory Bowel Diseases
SG187201A1 (en) * 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
CN105434476B (zh) * 2015-10-29 2019-02-15 广州知易生物科技有限公司 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用

Similar Documents

Publication Publication Date Title
JP2021529828A5 (enExample)
Edwards et al. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development
LaFond et al. Biological basis for syphilis
Subramaniam et al. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans
Butler et al. Immunomodulation therapy offers new molecular strategies to treat UTI
Lundgren et al. Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country
JP2012515551A5 (enExample)
JP2010516678A5 (enExample)
JP2010229138A5 (enExample)
JP2012502113A5 (enExample)
JP2010166921A5 (enExample)
Rodríguez-Iturbe et al. Acute postinfectious glomerulonephritis in children
Yeung Pathogenesis and treatment of Kawasaki's disease
JP2009536818A5 (enExample)
Moschioni et al. Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations
Tseng et al. Escherichia coli FimH adhesins act synergistically with PapGII adhesins for enhancing establishment and maintenance of kidney infection
Bhuvaneshwari et al. Emerging threat of scrub typhus: A call for greater awareness and research
Liu et al. Determining the immunological characteristics of a novel human monoclonal antibody developed against staphylococcal enterotoxin B
JP2012522522A5 (enExample)
Maina et al. Staphylococcal enterotoxin A has potent superantigenic and emetic activities but not diarrheagenic activity
CN101730545A (zh) 用于治疗肾病的化合物和方法
Im et al. First case of Bartonella henselae bacteremia in Korea
Jeon et al. Evaluation of enzyme-linked immunosorbent assay using milk samples as a potential screening test of bovine tuberculosis of dairy cows in Korea
Tiels et al. Monoclonal antibodies reveal a weak interaction between the F18 fimbrial adhesin FedF and the major subunit FedA
Mudter et al. Insight into Crohn’s disease pathomorphology